ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
FABP4 as a Mediator of Lipid Metabolism and Pregnant Uterine Dysfunction in Obesity.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Osteoarthritis: Epidemiology, Diagnosis, and Treatment.MedComm · 2026Review
- Gypenoside XLIX and Mitochondria-Associated ER Membranes in Non-Alcoholic Fatty Liver Disease: Mechanistic Insights and Emerging Perspectives.Molecules (Basel, Switzerland) · 2026Review
- FABP4 is highly expressed in preeclamptic placentas and regulates trophoblast lipid metabolism, mitochondrial function, and oxidative stress in vitro.BMC pregnancy and childbirth · 2026Article
- Body composition and adipokines in pregnant women: Associations with gestational diabetes mellitus risk.World journal of diabetes · 2026Article
- Blood and lymphatic vascular remodeling in intervertebral disc degeneration.Frontiers in immunology · 2026Review
- FABP4 as an immunometabolic hub in preeclampsia: from maternal-fetal interface to systemic inflammation.Frontiers in immunology · 2026Review
- FABP4 as a Mediator of Lipid Metabolism and Pregnant Uterine Dysfunction in Obesity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Obese pregnant women in late pregnancy are more susceptible to uterine smooth muscle dysfunction, but the underlying mechanisms remain elusive. Here, elevated levels of fatty acid binding protein 4 (FABP4) in the myometrium of obese pregnant women at term, high-fat diet (HFD)-induced obese mice, and palmitic acid-treated uterine smooth muscle cells (USMCs), are demonstrated. FABP4 plays a critical role in transporting fatty acids from the extracellular to the intracellular compartment. Mechanistically, obesity promotes excessive fatty acid uptake, leading to aberrant lipid accumulation and reduced ATP production in USMCs. These abnormalities stem from weakened coupling of mitochondria-associated membranes, which are essential for calcium, lipids, and metabolites exchange. Furthermore, adenoviral injection to elevate FABP4 levels in normal-diet mice mimicks the effects observed in HFD mice. Collectively, these findings highlight FABP4 as a key driver of myometrial dysfunction in obesity and a potential therapeutic target for improving labor outcomes in obese pregnancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.